Distinguished in Hypertension

Xiaolong M. Qi

1838 N Guanzhou Ave, 
Guangzhou, CN 
Distinguished in Hypertension
1838 N Guanzhou Ave, 
Guangzhou, CN 
OverviewLocationsClinical Research

Overview

Xiaolong Qi practices in Guangzhou, China. Qi is rated as a Distinguished expert by MediFind in the treatment of Hypertension. Their top areas of expertise are Portal Hypertension, Cirrhosis, Hypertension, Endoscopy, and Hepatectomy.

Their clinical research consists of co-authoring 237 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 46 articles and participated in 2 clinical trials in the study of Hypertension.

Locations

1838 N Guanzhou Ave, Guangzhou, 510515, China
Other Locations
1 Donggang West Rd, Lanzhou, 730000, China
1838 North Guangzhou Avenue, Guangzhou, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Radiomics-based Surrogate of Endoscopy (rEndosc) for Noninvasive Prediction of Esophageal Varices and Risk Stratification of Variceal Hemorrhage in Hepatitis B Virus-related Cirrhosis (CHESS1703)
Radiomics-based Surrogate of Endoscopy (rEndosc) for Noninvasive Prediction of Esophageal Varices and Risk Stratification of Variceal Hemorrhage in Hepatitis B Virus-related Cirrhosis (CHESS1703)
Enrollment Status: Withdrawn
Publish Date: June 19, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
Virtual Hepatic Venous Pressure Gradient (vHVPG) With CT Angiography (CHESS1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal Hypertension
Virtual Hepatic Venous Pressure Gradient (vHVPG) With CT Angiography (CHESS1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal Hypertension
Enrollment Status: Completed
Publish Date: January 08, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
Development and Validation of a Radiomics Signature for Clinically Significant Portal Hypertension in Cirrhosis (CHESS1701): a Prospective Multicenter Study
Development and Validation of a Radiomics Signature for Clinically Significant Portal Hypertension in Cirrhosis (CHESS1701): a Prospective Multicenter Study
Enrollment Status: Completed
Publish Date: January 08, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
View 2 Less Clinical Trials

237 Total Publications

Hepatic hypertension on-a-chip identifies GPR116 as a hydrostatic pressure mechanosensor to regulate vascular injury in cirrhosis.
Hepatic hypertension on-a-chip identifies GPR116 as a hydrostatic pressure mechanosensor to regulate vascular injury in cirrhosis.
Journal: Science advances
Published: November 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Qi's expertise for a condition
ConditionClose
View All 30 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile